Dr. Vinay (Vin) Bhaskar is responsible for investment identification, due diligence and business development, and brings extensive biotech experience to his current role at MPM. Vin served as startup COO of Werewolf Therapeutics and is a board member of Amphivena Therapeutics and Tizona Therapeutics.
Prior to joining MPM, Vin led external R&D for the oncology therapeutic area at Amgen, where he was instrumental in forging collaborations with companies such as Kite Pharma, Merck and Xencor. During this time, he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. He joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation and diligence for licensing and acquisition opportunities on the Asset Acquisition Team. Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in discovery research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies that spanned oncology, inflammation and cardiometabolic disease. Through these endeavors, he has gained broad expertise across all phases of drug discovery, early development and process sciences.
Vin holds a Ph.D. in Biochemistry from the University of California, Los Angeles and a B.S. in Biochemistry from the University of California, Davis.
Dr. Christiana (Chris) Bardon oversees the public equity component and is an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM. She is also the founder and managing member of Burrage Capital, a long/short equity manager in biotechnology and healthcare.
Previously, Chris was a health care analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM. She currently serves on the Harvard Medical School Board of Fellows and is a Trustee of the American Association for Cancer Research Foundation.
Chris earned her M.D. magna cum laude from Harvard Medical School and her M.B.A. from Harvard Business School. While at Harvard Medical School, she was the recipient of a Howard Hughes fellowship. She completed her residency in Internal Medicine at the Brigham and Women’s Hospital. She received her M.S./B.S. from the Massachusetts Institute of Technology.
Dr. Ansbert Gadicke is co-founder and Managing Director of MPM and its venture capital activities, as well as an investment committee member of its UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both public and private equities) managed by MPM. He is the driving force at MPM behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, iTeos Therapeutics (NASDAQ: ITOS) and AlloVir (NASDAQ: ALVR), both of which completed IPOs in 2020. MPM believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office.
Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and his co-founder Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. Ansbert is active in guiding MPM portfolio companies and serves as Director at Cullinan Oncology (NASDAQ: CGEM), NextPoint Therapeutics, Orna, and TCR2 Therapeutics (NASDAQ: TCRR) and as a Board Director at ElevateBio. He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.
Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.
Todd Foley, an experienced biotech investor, is a Managing Director at MPM Capital and serves on a number of MPM portfolio company boards, including Chiasma (NASDAQ: CHMA), CODA Biotherapeutics, Entrada Therapeutics, Iconic Therapeutics, Repare Therapeutics (NASDAQ: RPTX), Rhythm Pharmaceuticals (NASDAQ: RYTM), and Tetherex Pharmaceuticals. He previously served on the board of Semma Therapeutics, a potentially curative diabetes cell-therapy company founded by MPM and Doug Melton at Harvard, which was acquired by Vertex for $950M in 2019 in one of the largest ever preclinical M&A deals. He guided Selexys Pharmaceuticals to an acquisition by Novartis for $665M in 2016; Novartis launched the Selexys drug, Adakveo™ in late 2019 to treat sickle cell disease.
Todd has managed MPM’s strategic investment relationship with Novartis, which committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures.
Prior to joining MPM in 1999, Todd’s career in the life science industry included business development at Genentech (Roche) and management consulting with Arthur D. Little.
Todd earned his M.B.A. from Harvard Business School and his B.S. in Chemistry from the Massachusetts Institute of Technology.
Dr. Luke Evnin is co-founder and Managing Director of MPM. He co-founded MPM in 1997 with Ansbert Gadicke, M.D., and opened the San Francisco office in 1999.
Over the past 20+ years, the companies that MPM played a key role in building have delivered over 50 FDA approved drugs to the market, evidence of MPM’s success and commitment to funding breakthrough innovation to address unmet medical need.
In recent years, as a component of his MPM activities, Luke has been a co-founder and served as chairman of the board for seven MPM portfolio companies including Amphivena Therapeutics, Blade Therapeutics, Harpoon Therapeutics (NASDAQ: HARP), Maverick Therapeutics, Potenza Therapeutics, Tizona Therapeutics and Werewolf Therapeutics. He has contributed as a co-inventor in several of these companies as well as MPM portfolio company Oncorus (NASDAQ: ONCR). From October 2017 to June 2019, Dr. Evnin served as the interim Chief Executive Officer of Werewolf Therapeutics, Inc., one of MPM’s privately held biotechnology companies, where he continues to serves as chairman of its board of directors. In addition, he currently serves, on behalf of MPM Capital, as a director for eight other private companies.
Luke has also served on the board of directors of many other public and private companies over his 28-year venture capital career, including past service as a director of Syndax Pharmaceuticals, Inc., EnteroMedics Inc. (now known as ReShape Lifesciences Inc.), Epix Medical, Inc., Intercell AG, Metabasis Therapeutics, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Oscient Pharmaceuticals Corp., Pacira Pharmaceuticals Inc., Restore Medical, Inc. (acquired by Medtronic, Inc.), Sonic Innovations, Inc. and Signal Pharmaceuticals, Inc. (acquired by Celgene Corporation).
Luke also serves as chairman of the board of directors of the Scleroderma Research Foundation, a not-for-profit entity where he has contributed for over 20 years. He has devoted time to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics External Advisory Board at Princeton and at QB3 at the University of California- San Francisco. Also, in recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Luke and Ansbert are recipients of the 2017 Global Oncology Visionary Award.
Prior to co-founding MPM, he honed his skills as a venture capitalist at Accel Partners where he was involved in biopharmaceutical, medical device and healthcare service investing as an analyst and then General Partner at Accel Partners (1990-1997). Dr. Evnin holds a Ph.D. in Biochemistry (1990) from the University of California at San Francisco (UCSF) and an A.B. magna cum laude in Molecular Biology (1985) from Princeton University. He is an enthusiastic athlete (squash, tennis) and a wine collector.